Clinical Trial Update: An Evaluation of Aranesp® in Subjects With Anaemic Chronic Kidney Disease (CKD) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating Aranesp (darbepoetin alfa) in patients with anemia due to chronic kidney disease; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia of Chronic Kidney Disease
• Chronic Kidney Disease

Drugs mentioned

• ARANESP (DARBEPOETIN ALFA)

Snippet

Sponsor: Amgen | Conditions: Kidney Disease | Phase 3 | Status: COMPLETED